- Antybakteryjne kannabinoidy z Cannabis sativa: A Structure-Activity Study
- Aktywność przeciwdrobnoustrojowa Cannabis sativa L.
- Ekstrakcja kannabinoidów z rośliny konopia siewna L i jej potencjalne działanie przeciwdrobnoustrojowe
- Aktywność przeciwbakteryjna in vitro ekstraktów z liści Cannabis sativa w stosunku do niektórych selektywnych patogennych szczepów bakterii
- Marihuana, tetrahydrokannabinol i przeciwbakteryjne środki obronne płuc
- Kannabidiol i (-) Δ9-tetrahydrokannabinol to przeciwutleniacze neuroprotekcyjne
- * Mechanizm hamujący wpływ kanabidiolu na mikrosomalne utlenianie testosteronu w wątrobie samców szczurów
- Stres oksyradyczny, endokannabinoidy i miażdżyca
- Perspektywy terapii kannabinoidami w zaburzeniach zwojów podstawy
- Działanie kannabidiolu na niepokój i inne skutki wywoływane przez delta 9-THC u zdrowych osób
- Przeciwdepresyjne i przeciwlękowe działanie kannabidiolu: związek chemiczny Cannabis sativa
- Kannabidiol, składnik konopi siewnych, jako lek przeciwlękowy
- Kannabidiol jako potencjalne leczenie zaburzeń lękowych
- Kannabidiol zmniejsza niepokój wywołany symulowanymi wystąpieniami publicznymi u pacjentów z fobią społeczną, którzy nie byli wcześniej leczeni
- Kannabidiol regulacja emocji i przetwarzanie pamięci emocjonalnej: znaczenie w leczeniu zaburzeń związanych z lękiem i nadużywaniem substancji
- Związki kannabinoidowe w leczeniu zaburzeń lękowych: aktualna wiedza i perspektywy na przyszłość
- Centralny niedobór anandamidu przewiduje lęk wywołany stresem: odwrócenie zachowania poprzez zwiększenie endokannabinoidów
- Przewlekła blokada receptorów kannabinoidowych CB2 indukuje działania podobne do przeciwlękowych związane ze zmianami w receptorach GABA (A)
- Wpływ kanabidiolu (CBD) na regionalną krew mózgową
- Wpływ ipsapironu i kanabidiolu na lęk doświadczalny u ludzi
- Wyraźny wpływ Δ9-tetrahydrokannabinolu i kanabidiolu na aktywację neuronów podczas przetwarzania emocjonalnego
- Marihuana medyczna a zdrowie psychiczne: systematyczny przegląd z przewodnikiem
- Neuralne podstawy przeciwlękowych skutków kanabidiolu (CBD) w uogólnionym zespole lęku społecznego: raport wstępny
- Nadekspresja receptorów kannabinoidowych CB2 zmniejszyła podatność na niepokój i osłabione działanie anksjolityczne alprazolamu u myszy
- Leki roślinne stosowane w leczeniu zaburzeń lękowych, część 2: przegląd badań klinicznych wraz z potwierdzającymi dowodami przedklinicznymi
- Zredukowane zachowania lękowe wywołane przez genetyczne i farmakologiczne hamowanie enzymu degradującego endokannabinoidy hydrolazy amidu kwasu tłuszczowego (FAAH), w którym pośredniczą receptory CB1
- Anksjolityczny wpływ kannabidiolu na chronicznie zestresowane myszy zależy od neurogenezy hipokampu: zaangażowanie układu endokannabinoidowego
- Kannabidiol jako potencjalne leczenie zaburzeń lękowych
- Systematyczny przegląd skuteczności medycznej marihuany w zaburzeniach psychiatrycznych, ruchowych i neurodegeneracyjnych
- Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis
- Endokannabinoidy, karmienie i ssanie - z naszej perspektywy
- Endogenny system kannabinoidowy jako modulator przyjmowania pokarmu
- Podwzgórzowe neurony POMC promują karmienie indukowane kannabinoidami
- Wpływ pokarmu na farmakokinetykę doustnych kapsułek kanabidiolu u dorosłych pacjentów z padaczką oporną na leczenie
- Badanie dotyczące używania marihuany (marihuany) i zgłaszanych przez nich korzyści u mężczyzn z przewlekłym zapaleniem gruczołu krokowego / zespołem przewlekłego bólu miednicy
- Kannabinoidy i stwardnienie rozsiane
- Używanie konopi indyjskich w przypadku przewlekłego bólu nienowotworowego: wyniki badania prospektywnego
- Kompleksowy przegląd medycznej marihuany, kannabinoidów i terapeutycznych implikacji w medycynie i bólu głowy: jaka to była długa dziwna podróż…
- Delta-9-tetrahydrokannabinol-kannabidiol (Sativex): przegląd jego stosowania u pacjentów z umiarkowaną do ciężkiej spastycznością z powodu stwardnienia rozsianego
- Medyczna marihuana i przewlekły ból: przegląd podstawowych nauk i dowodów klinicznych
- Nowy syntetyczny, niepsychoaktywny kwas kannabinoidowy (HU-320) o właściwościach przeciwzapalnych w mysim zapaleniu stawów wywołanym kolagenem
- Receptory kannabinoidowe CB2 regulują ośrodkowe uczulenie i reakcje bólowe związane z chorobą zwyrodnieniową stawu kolanowego
- Antynocycepcja, w której pośredniczą kannabinoidy, jest wzmocniona u szczurów z chorobą zwyrodnieniową stawów kolanowych
- Receptor kannabinoidowy 2 jako potencjalny cel terapeutyczny w reumatoidalnym zapaleniu stawów
- Kannabinoid WIN ‑ 55,212‑2 mesylan hamuje aktywność ADAMTS ‑ 4 w ludzkich chondrocytach stawowych z chorobą zwyrodnieniową stawów poprzez hamowanie ekspresji syndekanu ‑ 1
- Kannabinoid WIN-55,212-2 mesylan hamuje indukowaną przez interleukinę-1b metaloproteinazę macierzy i tkankowy inhibitor ekspresji metaloproteinazy macierzy w ludzkich chondrocytach
- Charakterystyka układu receptorów kannabinoidowych w tkance maziowej i płynie u pacjentów z chorobą zwyrodnieniową stawów i reumatoidalnym zapaleniem stawów
- * Udział układu endokannabinoidowego w bólu związanym z chorobą zwyrodnieniową stawów
- Wstępna ocena skuteczności, tolerancji i bezpieczeństwa leku na bazie konopi siewnych (Sativex) w leczeniu bólu wywołanego reumatoidalnym zapaleniem stawów
- Zahamowanie produkcji czynnika martwicy nowotworu z komórek jednojądrzastych za pomocą nowego syntetycznego związku CLX-090717
- Niepsychoaktywny kannabidiol, będący składnikiem konopi, jest doustnym lekiem przeciw artretycznym w zapaleniu stawów wywołanym przez mysi kolagen
- Rola kannabinoidów w zapalnej modulacji alergicznych chorób układu oddechowego, bólu zapalnego i udaru niedokrwiennego
- Prowokacja alergenem zwiększa poziom anandamidu w płynie oskrzelowo-pęcherzykowym u pacjentów z astmą alergiczną
- Aktywacja receptorów kannabinoidowych zapobiega reakcjom astmopodobnym wywołanym przez antygen u świnek morskich
- Endogenni agoniści receptora kannabinoidowego hamują neurogenne stany zapalne dróg oddechowych świnek morskich
- Rozszerzające oskrzela działanie delta1-tetrahydrokannabinolu
- Ocena poziomu cytokin w surowicy i roli leczenia CBD w zwierzęcym modelu astmy
- Związek genu receptora kannabinoidowego (CNR1) z ADHD i zespołem stresu pourazowego
- Konopie siewne łagodzą objawy ADHD
- * Wywołana kannabinoidami warunkowa preferencja miejsca u szczura z samoistnym nadciśnieniem tętniczym - zwierzęcy model zespołu nadpobudliwości psychoruchowej z deficytem uwagi
- Wzmocnienie lekami w szczurzym modelu zespołu nadpobudliwości psychoruchowej z deficytem uwagi - szczur z samoistnym nadciśnieniem (SHR)
- Nowatorskie podejście do objawowego leczenia autyzmu
- Zmiany w układzie endokannabinoidowym w szczurzym modelu autyzmu z kwasem walproinowym
- Mutacje neuroliginy-3 związane z autyzmem często zakłócają sygnalizację endokannabinoidów tonów
- Krótki raport: marihuana bogata w kanabidiol u dzieci z zaburzeniami ze spektrum autyzmu i poważnymi problemami behawioralnymi - retrospektywne studium wykonalności
- Receptor kannabinoidowy typu 2, ale nie typu 1, jest podwyższony w jednojądrzastych komórkach krwi obwodowej dzieci dotkniętych zaburzeniami autystycznymi
- Konsekwencje zakłócenia układu kannabinoidowego i monoaminergicznego w mysim modelu zaburzeń ze spektrum autyzmu
- Słabe zachowania społeczne nastolatków po zapaleniu we wczesnym okresie życia są łagodzone przez wzmocnienie sygnalizacji anandamidowej
- Wadliwe zachowania społeczne i związane z zabawą u młodych i dorosłych szczurów po zmianach korowych u noworodków: skutki przewlekłego leczenia kannabinoidami w okresie dojrzewania płciowego
- Sygnalizacja endokannabinoidowa w autyzmie
- System endokannabinoidowy jako nowy cel terapeutyczny w leczeniu autyzmu
- Metoda przewidywania zaburzeń ze spektrum autyzmu na podstawie ekspresji receptorów kannabinoidowych i kannabinoidowych
- Mutacje stwierdzone u osób z autyzmem zakłócają sygnalizację endokannabinoidową w mózgu
- Różnice gatunkowe w receptorze kannabinoidowym 2 (gen CNR2): identyfikacja nowych izoform CB2 u ludzi i gryzoni, zróżnicowana ekspresja tkankowa i regulacja przez ligandy receptorów kannabinoidowych
- Celowanie w układ endokannabinoidowy w leczeniu zespołu łamliwego chromosomu X
- Układ endokannabinoidowy i zaburzenia ze spektrum autyzmu: wnioski z modeli zwierzęcych
- Rozprzęganie kompleksu sygnalizacyjnego endokannabinoidów w mysim modelu zespołu łamliwego chromosomu X.
- Stosowanie dronabinolu (delta-9-THC) w autyzmie: prospektywne pojedyncze studium przypadku z udziałem wczesnodziecięcego autystycznego dziecka
- Różnice w ludzkim genie receptora kannabinoidowego CNR1 modulują czas patrzenia szczęśliwych twarzy
- Kannabidiol jako sugerowany kandydat do leczenia zaburzeń ze spektrum autyzmu
- Wpływ kanabidiolu (CBD) na aktywność o niskiej częstotliwości i funkcjonalną łączność w mózgu osób dorosłych z zaburzeniami ze spektrum autyzmu i bez nich (ASD)
- Krótki raport: marihuana bogata w kanabidiol u dzieci z zaburzeniami ze spektrum autyzmu i poważnymi problemami behawioralnymi - retrospektywne studium wykonalności
- Obecny stan dowodów wykorzystania konopi siewnychw leczeniu zaburzeń ze spektrum autyzmu
- Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice
- Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol
- The Profile of Immune Modulation by Cannabidiol (CBD) Involves Deregulation of Nuclear Factor of Activated T Cells (NFAT)
- Immune Responses Regulated by Cannabidiol
- Immunity and CBD Oil: Does Cannabidiol Help or Hurt the Immune System?
Zespół autoimmunologicznej dysfunkcji autonomicznej
- Blurred Boundaries: The Therapeutics and Politics of Medical Marijuana
- Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs
- Cannabinoid CB2 receptor activation attenuates motor and autonomic function deficits in a mouse model of spinal cord injury
- * Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis
- Cannabinoid pharmacology: the first 66 years
- Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target
- * Cannabinoids and experimental models of multiple sclerosis
- Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta
- Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries
- Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart
- Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension
- Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells
- * The endocannabinoid system and its therapeutic exploitation
- The endocannabinoid system as an emerging target of pharmacotherapy
- Vascular targets for cannabinoids: animal and human studies
- Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement
- Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study
- siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycineinduced cell migration
- A systematic review and meta-analysis of the haemodynamic effects of cannabidiol
- A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study
- Blood pressure regulation by endocannabinoids and their receptors
- Is the cardiovascular system a therapeutic target for cannabidiol?
- * Safety and side effects of cannabidiol, a cannabis sativa constituent
Zdrowe kości
- Activation of cannabinoid receptor 2 enhances osteogenic differentiation of bone marrow derived from mesenchymal stem cells
- Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts
- Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro
- Cannabinoids and the skeleton: from marijuana to reversal of bone loss
- Cannabinoid receptors and the regulation of bone mass
- Mechanical and material properties of cortical and trabecular bone from cannabinoid receptor-1-null (Cnr1(-/-)) mice
- Peripheral cannabinoid receptor, CB2, regulates bone mass
- Protective Effects of Cannabidiol on Lesion-Induced Intervertebral Disc Degeneration
- Role of cannabinoids in the regulation of bone remodeling
- * The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling
- Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma
- *Cannabidiolic acid-mediated selective down-regulation of c-fos in highly aggressive breast cancer MDA-MB-231 cells: possible involvement of its down-regulation in the abrogation of aggressiveness
- Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
- Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy
- *Cannabinoids: A new hope for breast cancer therapy?
- Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition
- Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells
- Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent
- Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis
- Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer
- Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer
- The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
- Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer
- Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis
- * Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients
- Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial
- Cannabis use in HIV for pain and other medical symptoms
- Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS
- Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study
- * Effect of dronabinol therapy on physical activity in anorexia nervosa: a randomised, controlled trial
- Endocannabinoids, feeding and sucking – from our perspective
- Endogenous cannabinoid system as a modulator of food intake
- Hypothalamic POMC neurons promote cannabinoid-induced feeding
- The cannabinoids: An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection
- A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells
- A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme
- Anandamide Induces Apoptosis in Human Cells via Vanilloid Receptors
- Antiangiogenic activity of the endocannabinoid anandamide: Correlation to its tumor-suppressor efficacy
- Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration
- Anticancer mechanisms of cannabinoids
- Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy
- Anti-proliferative effects of anandamide in human hepatocellular carcinoma cells
- Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy
- Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma
- Antitumorigenic Effects of Cannabinoids beyond Apoptosis
- Association between cannabis use and the risk of bladder cancer: results from the California Men’s Health Study
- Cannabidiol (CBD) Priming Enhances Cisplatin Killing Of Cancer Cells
- Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells
- Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells
- Cannabidiol as potential anticancer drug
- Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival
- Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy
- Cannabidiol inhibits angiogenesis by multiple mechanisms
- Cannabidiol Inhibits Cancer Cell Invasion Via Upregulation Of Tissue Inhibitor Of Matrix Metalloproteinases-1
- Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism
- Cannabidiol Inhibits Growth and Induces Programmed Cell Death in Kaposi Sarcoma–Associated Herpesvirus Infected Endothelium
- Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1
- Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy
- Cannabidiolic acid-mediated selective down-regulation of c-fos in highly aggressive breast cancer MDA-MB-231 cells: possible involvement of its down-regulation in the abrogation of aggressiveness
- Cannabinoid-associated cell death mechanisms in tumor models (Review)
- Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma
- Cannabinoid Receptor Agonist as an Alternative Drug in 5-Fluorouracil-resistant Gastric Cancer Cells
- Cannabinoid receptor ligands as potential anticancer agents – high hopes for new therapies
- Cannabinoid Receptor-Mediated Apoptosis Induced by R()-Methanandamide and Win55,212-2 Is Associated with Ceramide Accumulation and p38 Activation in Mantle Cell Lymphoma
- Cannabinoid receptors as novel targets for the treatment of melanoma
- Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis
- Cannabinoids: A new hope for breast cancer therapy?
- Cannabinoids and cancer
- Cannabinoids and cancer: potential for colorectal cancer therapy
- Cannabinoids and cancer: pros and cons of an antitumour strategy
- Cannabinoids and ceramide: two lipids acting hand-by-hand
- Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators
- Cannabinoids as therapeutic agents in cancer: current status and future implications
- Cannabinoids, Endocannabinoids and Cancer
- Cannabinoids for Cancer Treatment: Progress and Promise
- Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes
- Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas
- Cannabinoids in the treatment of the cachexia-anorexia syndrome in palliative care patients
- Cannabinoids: potential antitumoral agents?
- Cannabinoids: potential anticancer agents
- Cannabinoids Protect Astrocytes from Ceramide-induced Apoptosis through the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway
- Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition
- Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells
- Cannabis and Cannabinoids (PDQ®) - National Cancer Institute | Patient
- Cannabis and Cannabinoids (PDQ®) - National Cancer Institute | Healthcare Professional
- Cannabis in cancer care
- Cannabis Extract Treatment for Terminal Acute Lymphoblastic Leukemia with a Philadelphia Chromosome Mutation
- CBD inhibits angiogenesis by multiple mechanisms
- Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer
- Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions
- Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group
- COX-2 and PPAR-g Confer Cannabidiol-Induced Apoptosis of Human Lung Cancer Cells
- Delta-9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo
- Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea
- Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized-double-blind, placebo-controlled pilot trial
- Differential role of cannabinoids in the pathogenesis of skin cancer
- Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells
- Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study
- Endocannabinoids and Cancer
- Endocannabinoids and fatty acid amides in cancer inflammation and related disorders
- Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (Review)
- Endocannabinoids as Guardians of Metastasis
- Endocannabinoids in endocrine and related tumours
- Enhancing the Activity of Cannabidiol and Other Cannabinoids In Vitro Through Modifications to Drug Combinations and Treatment Schedules
- Evaluation of the Cyclooxygenase Inhibiting Effects of Six Major Cannabinoids Isolated from Cannabis sativa
- Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells
- Expression and Functional Relevance of Cannabinoid Receptor 1 in Hodgkin Lymphoma
- Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by receptor activation
- High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma
- Id-1 Is a Key Transcriptional Regulator of Glioblastoma Aggressiveness and a Novel Therapeutic Target
- Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor
- In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma
- Increasing Antiproliferative Properties of Endocannabinoids in N1E-115 Neuroblastoma Cells through Inhibition of Their Metabolism
- Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1
- Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors
- Inhibition of tumor angiogenesis by cannabinoids
- Integrating cannabis into clinical cancer care
- Involvement of PPARc in the antitumoral action of cannabinoids on hepatocellular carcinoma
- Loss of Cannabinoid Receptor 1 Accelerates Intestinal Tumor Growth
- Marijuana Use and the Risk of Lung and Upper Aerodigestive Tract Cancers: Results of a Population-Based Case-Control Study
- Medical marijuana for cancer
- Medical Marijuana Use in Oncology
- Microarray and Pathway Analysis Reveal Distinct Mechanisms Underlying Cannabinoid-Mediated
- Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent
- Modulation of LPS-Induced Activation of BV-2 Microglial Cells
- Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain
- Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms
- NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)-Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies)
- Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation
- Potentiation of Cannabinoid-Induced Cytotoxicity in Mantle Cell Lymphoma through Modulation of Ceramide Metabolism
- Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid WIN-55,212-2
- Preparation and characterisation of biodegradable microparticles filled with THC and their antitumor efficacy on cancer cell lines
- Proapoptotic effect of endocannabinoids in prostate cancer cells
- Receptor-dependent and Receptor-independent Endocannabinoid Signaling: A Therapeutic Target for Regulation of Cancer Growth
- Regulation of nausea and vomiting by cannabinoids
- Structure-dependent inhibitory effects of synthetic cannabinoids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and skin tumour promotion in mice
- Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer
- Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling
- Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease
- Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer
- The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids
- The cannabinoids: An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection
- The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway
- The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model
- The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2
- The endocannabinoid system and cancer: therapeutic implication
- The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
- The Expression Level of CB1 and CB2 Receptors Determines Their Efficacy at Inducing Apoptosis in Astrocytomas
- The Medical Necessity for Medicinal Cannabis: Prospective, Observational Study Evaluating the Treatment in Cancer Patients on Supportive or Palliative Care
- The potential relevance of the endocannabinoid, 2- arachidonoylglycerol, in diffuse large B-cell lymphoma
- The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications
- The role of cannabinoids in the treatment of children with cancer
- The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells
- The use of cannabinoids as anticancer agents
- Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis
- Towards the use of cannabinoids as antitumour agents
- United States patent application publication for phytocannabinoids in the treatment of cancer
- Cancer cachexia and cannabinoids
- CBD and Cancer Studies – Summarized Exhaustive List
- Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro
- Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
- Cannabidiol in Humans—The Quest for Therapeutic Targets
- Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor
- Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid
- Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion
- * An ultra-low dose of tetrahydrocannabinol provides cardioprotection
- A systematic review and meta-analysis of the haemodynamic effects of cannabidiol
- A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study
- Blood pressure regulation by endocannabinoids and their receptors
- * Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function
- Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury
- Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory and cell death signaling pathways in diabetic cardiomyopathy
- Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs
- Cannabinoids in experimental stroke: a systematic review and meta-analysis
- Cannabis use: signal of increasing risk of serious cardiovascular disorders
- Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta
- Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries
- *Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
- Endocannabinoids Acting at Cannabinoid-1 Receptors Regulate Cardiovascular Function in Hypertension
- Is the cardiovascular system a therapeutic target for cannabidiol?
- *Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors
- Oxyradical Stress, Endocannabinoids, and Atherosclerosis
- Role of Endocannabinoids and Cannabinoid-1 Receptors in Cerebrocortical Blood Flow Regulation
- *The effect of cannabidiol on ischemia/reperfusion-induced ventricular arrhythmias: the role of the adenosine A1 receptors
- * The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic–ischemic brain damage in mice is mediated by CB2 and adenosine receptors
- Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke
- Vascular targets for cannabinoids: animal and human studies
- Allosteric Modulation of the Cannabinoid CB1 Receptor
- Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor
- Cannabinoid CB1 receptor binding and acetylcholinesterase inhibitory activity of Sceletium tortuosum L.
- Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis
- Enhanced acetylcholine release in the hippocampus of cannabinoid
- Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid
- Immunohistochemical analysis of cannabinoid receptor 1 expression in steatotic rat livers
- Loss of Cannabinoid Receptor 1 Accelerates Intestinal Tumor Growth
- Presynaptically Located CB1 Cannabinoid Receptors Regulate GABA Release from Axon Terminals of Specific Hippocampal Interneurons
- Acute upregulation of neuronal mitochondrial type-1 cannabinoid receptor and it’s role in metabolic defects and neuronal apoptosis after TBI
- * An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
- Cannabinoid agonist rescues learning and memory after a traumatic brain injury
- * Cannabinoids and brain injury: therapeutic implications
- CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice
- Early increase of cannabinoid receptor density after experimental traumatic brain injury in the newborn piglet
- * Effect of Marijuana Use on Outcomes in Traumatic Brain Injury
- Endocannabinoids: A Promising Impact for Traumatic Brain Injury
- Endocannabinoids and traumatic brain injury
- Estradiol decreases cortical reactive astrogliosis after brain injury by a mechanism involving cannabinoid receptors
- Mechanisms of cannabidiol neuroprotection in hyopoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors
- Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist
- * The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines
- The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors
- β-Caryophyllene Inhibits Dextran Sulfate Sodium-Induced Colitis in Mice through CB2 Receptor Activation and PPARγ Pathway
- * Acute effects of smoked marijuana and oral delta9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects
- * Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors
- Brochodiltor Effect of Δ1-Tetrahydrocannabinol
- Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury
- Cannabinoid effects on ventilation and breathlessness: a pilot study of efficacy and safety
- Cannabinoids, endocannabinoids, and related analogs in inflammation
- Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors
- Cannabinoids Tetrahydrocannabinol and Cannabidiol Differentially Inhibit the Lipopolysaccharide-activated NF-κB and Interferon-β/STAT Proinflammatory Pathways in BV-2 Microglial Cells
- Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor
- * Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury
- * CB2 receptors regulate natural killer cells that limit allergic airway inflammation in a murine model of asthma
- Effects of cannabis on pulmonary structure, function and symptoms
- Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors
- Impact of cannabis, cannabinoids, and endocannabinoids in the lungs
- Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation
- Marijuana and chronic obstructive lung disease: a population-based study
- Monoacylglycerol Lipase (MAGL) Inhibition Attenuates Acute Lung Injury in Mice
- * Preclinical assessment of novel therapeutics on the cough reflex: cannabinoid agonists as potential antitussives
- Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
- Cannabinoids and gastrointestinal motility: Animal and human studies
- Cannabinoids and the gut: New developments and emerging concepts
- Cannabis finds its way into treatment of Crohn’s disease
- CBD in inflammatory bowel diseases: a brief overview
- CBD reduces intestinal inflammation through the control of neuroimmune axis
- Endocannabinoids and the gastrointestinal tract
- Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis
- Low-dose cannabidiol is safe but not effective in the treatment for Crohn's Disease, a randomized controlled trial
- Manipulation of the endocannabinoid system in colitis: A comprehensive review
- The effects of Delta-tetrahydrocannabinol and CBD alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis
- Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice
- Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells
- Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors
- Induction of Apoptosis by Cannabinoids in Prostate and Colon Cancer Cells Is Phosphatase Dependent
- The cannabinoid δ9-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells
- The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2
- The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells
- Activation of Cannabinoid Receptor 2 Prevents Colitis-Associated Colon Cancer through Myeloid Cell De-activation Upstream of IL-22 Production
- Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
- Cannabinoids and gastrointestinal motility: Animal and human studies
- Cannabinoids and the gut: New developments and emerging concepts
- Cannabis Alleviates Symptoms Of Crohn’s Disease
- Cannabis for Inflammatory Bowel Disease
- Cannabis Finds Its Way into Treatment of Crohn’s Disease
- Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study
- CBD in inflammatory bowel diseases: a brief overview
- CBD reduces intestinal inflammation through the control of neuroimmune axis
- Endocannabinoids and the gastrointestinal tract
- Endocannabinoid system acts as a regulator of immune homeostasis in the gut
- Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis
- Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study
- Low-dose cannabidiol is safe but not effective in the treatment for Crohn's Disease, a randomized controlled trial
- Manipulation of the endocannabinoid system in colitis: A comprehensive review
- Marijuana use patterns among patients with inflammatory bowel disease
- Protective effect of cannabidiol against cadmium hepatoxicity in rats
- The effects of Δ9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis
- Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats
- Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice
- Treatment of Crohn’s Disease with Cannabis: An Observational Study
- A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme
- Activity of cannabis in relation to its delta'-trans-tetrahydro-cannabinol content
- Adolescent Exposure to Chronic Delta-9-Tetrahydrocannabinol Blocks Opiate Dependence in Maternally Deprived Rats
- BRONCHODILATOR EFFECT OF Δ1-TETRAHYDROCANNABINOL
- Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants
- Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis
- Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival
- D9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo
- D9-Tetrahydrocannabinol Prevents Methamphetamine-Induced Neurotoxicity
- Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol
- Fatty Acid Binding Proteins (FABPs) are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
- Histone Modifications Are Associated with Delta (9)-tetrahydrocannabinol-Mediated Alterations in Antigen-Specific T Cell Responses
- Influence of Treatment of Tourette Syndrome with Δ9-Tetrahydrocannabinol (Δ9-THC) on Neuropsychological Performance
- Neuroprotection by Δ9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity
- Opposite Effects of D-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology
- The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin
- The effects of Δ9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis
- Treatment of Tourette-Syndrome with Δ9-Tetrahydrocannabinol (THC): a randomized crossover trial
- Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy
- Cannabinoids Regulate Bcl-2 and Cyclin D2 Expression in Pancreatic β Cells
- Novel Study Reports Marijuana Users Have Better Blood Sugar Control
- Presence of functional cannabinoid receptors in human endocrine pancreas
- The Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications
- The endocannabinoid system in obesity and type 2 diabetes
- Cannabidiol arrests onset of autoimmune diabetes in NOD mice
- Cannabidiol lowers incidence of diabetes in non-obese diabetic mice
- Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action
- *Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study)
- *Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors
- *Cannabidiol—transdermal delivery and anti-inflammatory effect in a murine model
- *Cannabinoid agonists attenuate capsaicin‐induced responses in human skin
- Cannabinoid system in the skin – a possible target for future therapies in dermatology
- Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB 1 receptors
- *Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study
- Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin
- The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities
- The role of cannabinoids in dermatology
- Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus
- Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation
- Regulation of nausea and vomiting by cannabinoids
- The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus
- The Nonpsychoactive Cannabinoid Cannabidiol Inhibits 5-Hydroxytryptamine3A Receptor-Mediated Currents in Xenopus laevis Oocytes
- Biphasic Effects of Cannabinoids on Acetylcholine Release in the Hippocampus: Site and Mechanism of Action
- Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro
- Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor
- Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors
- Cannabinoid pharmacology: the first 66 years
- Cannabinoid Receptors CB1 and CB2 Form Functional Heteromers in Brain
- Cannabis, a complex plant: different compounds and different effects on individuals
- Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System
- Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions
- Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes
- Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol
- Endocannabinoid Signaling Regulates Sleep Stability
- Endothelium-dependent metabolism by endocannabinoid hydrolases and cyclooxygenases limits vasorelaxation to anandamide and 2-arachidonoylglycerol
- Enhanced discriminative stimulus effects of 9-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys
- Estrogen Receptor Beta and 2-arachidonoylglycerol Mediate the Suppressive Effects of Estradiol on Frequency of Postsynaptic Currents in Gonadotropin-Releasing Hormone Neurons of Metestrous Mice: An Acute Slice Electrophysiological Study
- Evidence that the plant cannabinoid cannabigerol is a highly potent a2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist
- Fatty Acid Binding Proteins (FABPs) are Intracellular Carriers for Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
- Mitochondria: a possible nexus for the regulation of energy homeostasis by the endocannabinoid system
- Modulating the endocannabinoid system in human health and disease: successes and failures
- Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol
- Targeting the endocannabinoid system with cannabinoid receptor agonists- pharmacological strategies and therapeutic possibilities
- The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin
- The Endocannabinoid-CB Receptor System: Importance for development and in pediatric disease
- The Endocannabinoid System as an Emerging Target of Pharmacotherapy
- The Endocannabinoid System, Cannabinoids, and Pain
- The endocannabinoid system in normal and pathological brain ageing
- The endogenous cannabinoid system and its role in nociceptive behavior
- The orphan receptor GPR55 is a novel cannabinoid receptor
- Estrogen Receptor Beta and 2-arachidonoylglycerol Mediate the Suppressive Effects of Estradiol on Frequency of Postsynaptic Currents in Gonadotropin-Releasing Hormone Neurons of Metestrous Mice: An Acute Slice Electrophysiological Study
- Presence of functional cannabinoid receptors in human endocrine pancreas
- The effects of delta9-tetrahydrocannabinol and cannabidiol on the metabolism of gonadal steroids in the rat
- Activation of the Cannabinoid Type-1 Receptor Mediates the Anticonvulsant Properties of Cannabinoids in the Hippocampal Neuronal Culture Models of Acquired Epilepsy and Status Epilepticus
- Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome
- Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo
- Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model
- Cannabidiol for epilepsy: a new indication for an old drug
- Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
- Cannabidiol Rescues Acute Hepatic Toxicity and Seizure Induced by Cocaine
- Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression
- Cannabidivarin is anticonvulsant in mouse and rat
- Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism
- Cannabinoids for pediatric epilepsy? Up in smoke or real science?
- Cannabis-based products for pediatric epilepsy: An updated systematic review
- Cannabis and Epilepsy
- Cannabis, Cannabinoids and Tinnitus
- Cannabis In The Management And Treatment Of Seizures And Epilepsy: A Scientific Review
- CBD: A New Hope?
- CBD-enriched medical cannabis for intractable pediatric epilepsy; The current Israeli experience
- Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
- Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis
- Efficacy of cannabinoids in paediatric epilepsy
- Evidence for Cannabis and Cannabinoids for Epilepsy: A Systematic Review of Controlled and Observational Evidence
- On the application of cannabis in paediatrics and epileptology
- Parent use of cannabis for intractable pediatric epilepsy: Everyday empiricism and the boundaries of scientific medicine
- Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy
- Redistribution of CB1 Cannabinoid Receptors in the Acute and Chronic Phases of Pilocarpine-Induced Epilepsy
- Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy
- The case for assessing cannabidiol in epilepsy
- The case for medical marijuana in epilepsy
- The Endogenous Cannabinoid System Regulates Seizure Frequency and Duration in a Model of Temporal Lobe Epilepsy
- The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids
- Understanding Cannabinoids and Epilepsy
- Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials
- Pharmacology of cannabinoids in the treatment of epilepsy
- Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection
- Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism
- Cannabidivarin is anticonvulsant in mouse and rat
- Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: Pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels
- Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials
- What to know about CBD oil for seizures
- Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome
- Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy
- Association of Herbal Cannabis Use With Negative Psychosocial Parameters in Patients With Fibromyalgia
- Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions
- Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes
- Marijuana Rated Most Effective for Treating Fibromyalgia
- Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes
- Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis
- Cannabinoids and the gastrointestinal tract
- Cannabis Alleviates Symptoms Of Crohn’s Disease
- Cannabis Finds Its Way into Treatment of Crohn’s Disease
- Cannabis use amongst patients with inflammatory bowel disease
- Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism
- Marijuana Use Patterns Among Patients with Inflammatory Bowel Disease
- Pro-resolution, protective and anti-nociceptive effects of a cannabis extract in the rat gastrointestinal tract
- The effects of Δ9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis
- Treatment of Crohn’s Disease with Cannabis: An Observational Study
- Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
- Cannabinoids in health and disease
- Cannabis sativa: The Plant of the Thousand and One Molecules
- Future of Cannabis and Cannabinoids in Therapeutics
- Medical Marijuana: Clearing Away the Smoke
- Pharmacological actions and therapeutic uses of cannabis and cannabinoids
- Phytocannabinoids beyond the Cannabis plant – do they exist?
- Plant cannabinoids: a neglected pharmacological treasure trove
- Review on clinical studies with cannabis and cannabinoids 2010-2014
- Safety and Toxicology of Cannabinoids
- Therapeutic aspects of cannabis and cannabinoids
- Therapeutic Benefits of Cannabis: A Patient Survey
- NIDA Research on the Therapeutic Benefits of Cannabis and Cannabinoids
The Therapeutic Potential of Cannabis and Cannabinoids
- A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme
- Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival
- Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells
- Id-1 Is a Key Transcriptional Regulator of Glioblastoma Aggressiveness and a Novel Therapeutic Target
- A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma
- Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines
- Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect
- Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism
- Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells
- Cannabinoids Inhibit Glioma Cell Invasion by Down-regulating Matrix Metalloproteinase-2 Expression
- Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas
- Δ9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells
- Inhibition of Glioma Growth in Vivo by Selective Activation of the CB2 Cannabinoid Receptor
- Cannabinoids in Glioblastoma Therapy: New Applications for Old Drugs
- *Cannabinoids decrease the th17 inflammatory autoimmune phenotype
- *Neuroprotective activity of cannabinoid receptor-2 against oxidative stress and apoptosis in rat pups having experimentally-induced congenital hypothyroidism
- *The CB1 receptor is required for the establishment of the hyperlocomotor phenotype in developmentally-induced hypothyroidism in mice
- Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro
- The effect of delta-9-tetrahydrocannabinol on herpes simplex virus replication
- Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside
- Cannabis May Help Combat Cancer-causing Herpes Viruses
- Effects of Cannabinoids on T-cell Function and Resistance to Infection
- Suppressive effect of delta-9-tetrahydrocannabinol on herpes simplex virus infectivity in vitro
- Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro
- Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis
- Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties
- Cannabinoids and the immune system
- CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies
- D9-Tetrahydrocannabinol-Induced Apoptosis in the Thymus and Spleen as a Mechanism of Immunosuppression in Vitro and in Vivo
- Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations
- Histone Modifications Are Associated with Delta (9)-tetrahydrocannabinol-Mediated Alterations in Antigen-Specific T Cell Responses
- Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol – studies in BV-2 microglia and encephalitogenic T cells
- Anti-Inflammatory Role of Cannabidiol and O-1602 in Cerulein-Induced Acute Pancreatitis in Mice
- Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy
- Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
- Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
- Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement
- Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis
- Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study
- Cannabinoid CB2 receptors in human brain inflammation
- Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation
- Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis
- Cannabinoids in models of chronic inflammatory conditions
- Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability
- Cannabinoids Reduce Markers of Inflammation and Fibrosis in Pancreatic Stellate Cells
- Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
- Cannabinomimetic Control of Mast Cell Mediator Release: New Perspective in Chronic Inflammation
- Clinical Implications for Cannabinoid Use in the Rheumatic Diseases
- Evaluation of the Cyclooxygenase Inhibiting Effects of Six Major Cannabinoids Isolated from Cannabis sativa
- Overcoming the Bell‐Shaped Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol
- Oxyradical Stress, Endocannabinoids, and Atherosclerosis
- Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol
- The effects of Δ9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis
- Cannabinoids, Endocannabinoids, and Related Analogs in Inflammation
- Inflammation and aging: can endocannabinoids help?
- Cannabinoid Delivery Systems for Pain and Inflammation Treatment
- Cannabinoids as novel anti-inflammatory drugs
- A clinical study showed that cannabis produces significant clinical benefits in patients with Crohn’s disease, including a reduction in pain sensation, nausea relief and reduce the feeling of unpleasantness.
- Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions
- Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes
Choroby niedokrwienne
- Activation of Cannabinoid CB2 Receptor–Mediated AMPK-CREB Pathway Reduces Cerebral Ischemic Injury
- Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion
- Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury
- Effects of Cannabidiol and Hypothermia on Short-Term Brain Damage in New-Born Piglets after Acute Hypoxia-Ischemia
- HU211, a Novel Noncompetitive NMethylDAspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat
- Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT1A and CB2 receptors
- The Cannabinoid Agonist Win55212 Reduces Brain Damage in an In Vivo Model of Hypoxic-Ischemic Encephalopathy in Newborn Rats
- Therapeutic potential of cannabidiol against ischemia/reperfusion liver injury in rats
- Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke
- Update on the Role of Cannabinoid Receptors after Ischemic Stroke
- Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
- CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies
- Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor
- Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection
- The endocannabinoid system as a target for the treatment of neurodegenerative disease
- The Endocannabinoid System Is Dysregulated in Multiple Sclerosis and in Experimental Autoimmune Encephalomyelitis
- Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis
- *γ-Irradiation Enhances Apoptosis Induced by Cannabidiol, a Non-psychotropic Cannabinoid, in Cultured HL-60 Myeloblastic Leukemia Cells
- Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression
- Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study
- Cannabinoids induce incomplete maturation of cultured human leukemia cells
- *Cannabinoids: potential anticancer agents
- *Cannabis-induced cytotoxicity in leukemia cell lines: the role of the cannabinoid receptors and the MAPK pathway
- Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation
- D9-Tetrahydrocannabinol-Induced Apoptosis in Jurkat Leukemia T Cells Is Regulated by Translocation of Bad to Mitochondria
- Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
- Enhancing the Activity of Cannabidiol and Other Cannabinoids In Vitro Through Modifications to Drug Combinations and Treatment Schedule
- *Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach
- Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice
- Endocannabinoids in Liver Disease
- Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells
- Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol
- Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis
- Cannabinoids for Cancer Treatment: Progress and Promise
- COX-2 and PPAR-g Confer Cannabidiol-Induced Apoptosis of Human Lung Cancer Cells
- Δ9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo
- Marijuana Use and the Risk of Lung and Upper Aerodigestive Tract Cancers: Results of a Population-Based Case-Control Study
- Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro
- Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis
- Antibacterial activity of Δ9-tetrahydrocannabinol and cannabidiol
- Antibacterial Cannabinoids from Cannabis sativa: A Structure-Activity Study
- Antimicrobial Activity of Cannabis sativa L.
- Extraction of cannabinoids from cannabis sativa L plant and its potential antimicrobial activity
- In vitro antibacterial activity of Cannabis sativa leaf extracts to some selective pathogenicbacterial strains
- Cannabinoids in the management of difficult to treat pain
- Book review: “Cannabis for Lyme disease and related conditions”
- FUNDAMENTAL PRINCIPLES OF USING CANNABIS TO TREAT LYME AND RELATED CONDITIONS
- Mediation of Cannabidiol anti-inflammation in the Retina by Equilibrative Nucleoside Transporter and A2A Adenosine Receptor*
- Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes
- Neuroprotective Effect of(−)Δ9-Tetrahydrocannabinol and Cannabidiol in N-Methyl-d-Aspartate-Induced Retinal Neurotoxicity
- Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study
- Non-acute (residual) neurocognitive effects of cannabis Use: A meta-analytic study
- On Disruption of Fear Memory by Reconsolidation Blockade: Evidence from Cannabidiol Treatment
- The cannabinoid receptor agonist WIN 55-212-2 facilitates the extinction of contextual fear memory and spatial memory in rats
- Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons
- Adolescent Exposure to Chronic Delta-9-Tetrahydrocannabinol Blocks Opiate Dependence in Maternally Deprived Rats
- β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice
- Brain CB2 Receptors: Implications for Neuropsychiatric Disorders
- Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
- Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances
- Cannabidiol as a potential treatment for psychosis
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- Cannabidiol, neuroprotection and neuropsychiatric disorders
- Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice
- Cannabinoid CB1 receptors in the dorsal hippocampus and prelimbic medial prefrontal cortex modulate anxiety-like behavior in rats: Additional evidence
- Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential
- Cannabis as a substitute for alcohol and other drugs
- CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex
- Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice
- Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
- Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain
- Influence of Treatment of Tourette Syndrome with Δ9-Tetrahydrocannabinol (Δ9-THC) on Neuropsychological Performance
- Joint Effects: A Pilot Investigation of the Impact of Bipolar Disorder and Marijuana Use on Cognitive Function and Mood
- Long term marijuana users seeking medical cannabis in California (2001–2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants
- Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
- Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report - ResearchGate
- Opposite Effects of D-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology
- The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
- The Development of Cannabidiol as a Psychiatric Therapeutic: A Review of Its Antipsychotic Efficacy and Possible Underlying Pharmacodynamic Mechanisms
- The endocannabinoid system and emotional Processing: A pharmacological fMRI study with Δ9-tetrahydrocannabinol
- Therapeutical use of the cannabinoids in psychiatry
- Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model
- Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions
- Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions
- Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It’s Been
- Effects of anandamide in migraine: data from an animal model
- Endocannabinoids in the Brainstem Modulate Dural Trigeminovascular Nociceptive Traffic via CB1 and “Triptan” Receptors: Implications in Migraine
- The endocannabinoid system and migraine
- Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes
- Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol – studies in BV-2 microglia and encephalitogenic T cells
- Cannabidiol affects the expression of genes involved in zinc homeostasis in BV-2 microglial cells
- Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure
- Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis
- Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT1A and CB2 receptors
- A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules
- Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
- Cannabinoid Modulation of Neuroinflammatory Disorders
- Cannabinoids and multiple sclerosis
- Cannabinoids control spasticity and tremor in a multiple sclerosis model
- Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
- Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
- Cannabinoids in the management of spasticity associated with multiple sclerosis
- Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
- CBD provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
- Clinical experiences with cannabinoids in spasticity management in multiple sclerosis
- Effects of cannabis on cognitive function in patients with multiple sclerosis
- Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study
- Oromucosal delta9-THC/CBD for neuropathic pain associated with multiple sclerosis
- Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study
- Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation
- Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial
- Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity
- THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms
- The cannabinoids: An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection
- The effect of cannabis on tremor in patients with multiple sclerosis
- The Endocannabinoid System Is Dysregulated in Multiple Sclerosis and in Experimental Autoimmune Encephalomyelitis
- Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis
- Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review
- Cannabidiol to Improve Mobility in People with Multiple Sclerosis
- The therapeutic potential of cannabis and cannabinoids
- Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects
- Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT1A somatodendritic autoreceptors in the dorsal raphe nucleus
- Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation
- Cannabinoid Regulation of Acute and Anticipatory Nausea
- Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews
- Regulation of nausea and vomiting by cannabinoids
- Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders
- Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor
- Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations
- "The Therapeutic Potential of Cannabinoids for Movement
Disorders | Nervous System"
- Activation of Type 1 Cannabinoid Receptor (CB1R) Promotes Neurogenesis in Murine Subventricular Zone Cell Cultures
- Cannabidiol and (−)Δ9-tetrahydrocannabinol are neuroprotective antioxidants
- Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid
- Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice
- Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement
- Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis
- Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
- Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects
- Cannabinoids: Well-Suited Candidates for the Treatment of Perinatal Brain Injury
- CB1 and CB2 Cannabinoid Receptor Antagonists Prevent Minocycline-Induced Neuroprotection Following Traumatic Brain Injury in Mice
- CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
- Comparison of Cannabidiol, Antioxidants, and Diuretics in Reversing Binge Ethanol-Induced Neurotoxicity
- Endocannabinoid Signaling In Neurotoxicity And Neuroprotection
- Endocannabinoids and traumatic brain injury
- Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection
- Long-term behavioral and biochemical effects of an ultra-low dose of Δ9-tetrahydrocannabinol (THC): neuroprotection and ERK signaling
- Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity
- Neuroprotection by Δ9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo Excitotoxicity
- Neuroprotective and Blood-Retinal Barrier-Preserving Effects of Cannabidiol in Experimental Diabetes
- Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells
- Neuroprotective Effect of(−)Δ9-Tetrahydrocannabinol and Cannabidiol in N-Methyl-d-Aspartate-Induced Retinal Neurotoxicity
- Nonpsychoactive Cannabidiol Prevents Prion Accumulation and Protects Neurons against Prion Toxicity
- Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist
- Prospects for cannabinoid therapies in basal ganglia disorders
- Protective effects of Δ9-tetrahydrocannabinol against N-methyl-D-aspartate-induced AF5 cell death
- Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity
- The Cannabinoid WIN55212-2 Promotes Neural Repair After Neonatal Hypoxia–Ischemia
- The cannabinoids: An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection
- The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K Akt mTORC1 BDNF pathway
- The endocannabinoid 2-AG protects the blood–brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines
- The endocannabinoid system as a target for the treatment of neurodegenerative disease
- The endocannabinoid system in normal and pathological brain ageing
- Δ9-Tetrahydrocannabinol Prevents Methamphetamine-Induced Neurotoxicity
- An Increase in the Omega-6-Omega-3 Fatty Acid Ratio Increases the Risk for Obesity
- Cannabinoid receptor 2 as anti-obesity target: inflammation, fat storage and browning modulation
- Pathophysiological role of host microbiota in the development of obesity
- The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity
- Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol
- Amygdala activity contributes to the dissociative effect of cannabis on pain perception
- Assessing efficacy of non-opioid analgesics in experimental pain models in healthy volunteers- an updated review
- Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy
- Cannabinoid CB2 Receptors Regulate Central Sensitization and Pain Responses Associated with Osteoarthritis of the Knee Joint
- Cannabinoid receptors and pain
- Cannabinoids delivery systems based on supramolecular inclusion complexes and polymeric nanocapsules for treatment of neuropathic pain
- Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials
- Cannabinoids in the management of difficult to treat pain
- Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
- Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS)
- Clinical Implications for Cannabinoid Use in the Rheumatic Diseases
- Impact of Marijuana on Children and Adolescents
- Injury, Pain, and Prescription Opioid Use Among Former National Football League (NFL) Players
- Overcoming the Bell‐Shaped Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol
- Prescribing cannabis for harm reduction
- Role of Cannabinoids in Pain Management
- Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
- Smoked cannabis for chronic neuropathic pain: a randomized controlled trial
- Stable dose cannabinoid medicine GW
- Survey Results of Pain Treatments in Adults with Cerebral Palsy
- Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine
- Targeting CB2 receptors and the endocannabinoid system for the treatment of pain
- The Endocannabinoid System, Cannabinoids, and Pain
- The endogenous cannabinoid system and its role in nociceptive behavior
- The Pharmacologic and Clinical Effects of Medical Cannabis
- Use of prescription pain medications among medical cannabis patients: comparisons of pain levels, functioning, and patterns of alcohol and other drug use
- δ-Ctenitoxin-Pn1a, a Peptide from Phoneutria nigriventer Spider Venom, Shows Antinociceptive Effect Involving Opioid and Cannabinoid Systems, in Rats
- A Balanced Approach for Cannabidiol Use in Chronic Pain
- Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors
- The Analgesic Potential of Cannabinoids
- Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside
- Cannabinoid Delivery Systems for Pain and Inflammation Treatment
- The therapeutic potential of cannabis and cannabinoids
- Cannabinoids in the management of difficult to treat pain
- Anti-Inflammatory Role of Cannabidiol and O-1602 in Cerulein-Induced Acute Pancreatitis in Mice
- Cannabinoids Ameliorate Pain and Reduce Disease Pathology in Cerulein-Induced Acute Pancreatitis
- Cannabinoids Reduce Markers of Inflammation and Fibrosis in Pancreatic Stellate Cells
- Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes
- A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson’s disease
- Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial
- Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures
- Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease
- Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets
- Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease
- Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection
- Self-Reported Efficacy of Cannabis and Other Complementary Medicine Modalities by Parkinson's Disease Patients in Colorado
- Survey on Cannabis Use in Parkinson’s Disease: Subjective Improvement of Motor Symptoms
- The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1-2 phosphorylation in 6-OHDA-lesioned rats
- The influence of cannabinoids on generic traits of neurodegeneration
- Targeting CB 1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson's Disease
- Expression of GPR55 and either cannabinoid CB 1 or CB 2 heteroreceptor complexes in the caudate, putamen, and accumbens nuclei of control, parkinsonian, and dyskinetic non-human primates
- Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties
- Activation of cannabinoid CB1 receptors induces glucose intolerance in rats
- Cannabinoid Receptor 1 Gene Polymorphisms and Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome and in Healthy Controls
- *Decreased expression of fatty acid amide hydrolase in women with polycystic ovary syndrome
- *Effects of cannabinoid antagonist-induced weight loss in polycystic ovarian syndrome (PCOS) patients
- Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss
- *Endocannabinoid system activation may be associated with insulin resistance in women with polycystic ovary syndrome
- Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
- The endocannabinoid pathway and the female reproductive organs
- Cannabinoids Prevent the Effects of a Footshock Followed by Situational Reminders on Emotional Processing
- Changes of endocannabinoid plasma levels following type I trauma: A prospective pilot study
- Elevated Brain Cannabinoid CB1 Receptor Availability in Posttraumatic Stress Disorder- A Positron Emission Tomography Study
- On Disruption of Fear Memory by Reconsolidation Blockade: Evidence from Cannabidiol Treatment
- PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program
- A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol
- Activity of cannabis in relation to its delta'-trans-tetrahydro-cannabinol content
- An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity
- Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival
- Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts
- Overcoming the Bell‐Shaped Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol
- Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects
- Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines
- Fetal Alcohol Spectrum Disorder: Potential Role of Endocannabinoids Signaling
- Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain
- Multiple Roles for the Endocannabinoid System During the Earliest Stages of Life: Pre- and Postnatal Development
- The Endocannabinoid-CB Receptor System: Importance for development and in pediatric disease
- Cannabinoid Receptor Agonist-induced Apoptosis of Human Prostate Cancer Cells LNCaP Proceeds through Sustained Activation of ERK12 Leading to G1 Cell Cycle Arrest
- Cannabinoid receptor as a novel target for the treatment of prostate cancer
- Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R( þ )-Methanandamide and JWH-015: Involvement of CB2
- Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms
- Proapoptotic effect of endocannabinoids in prostate cancer cells
- The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications
- Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms
- The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications
- Cannabinoids inhibit human keratinocyte proliferation through a non-CB1-CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis
- Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation
- Mechanisms of Cannabinoids and Potential Applicability to Skin Diseases
- Endocannabinoids modulate human epidermal keratinocyte proliferation and survival via the sequential engagement of cannabinoid receptor-1 and transient receptor potential vanilloid-1
- Association Between Marijuana Exposure and Pulmonary Function Over 20 Years
- Bronchodilator Effect Of Δ1-Tetrahydrocannabinol
- Cannabinoid effects on ventilation and breathlessness: a pilot study of efficacy and safety
- Does smoking marijuana increase the risk of chronic obstructive pulmonary disease
- Effects of Marijuana Smoking on the Lung
- Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation
- Marijuana and chronic obstructive lung disease: a population-based study
- Monoacylglycerol Lipase (MAGL) Inhibition Attenuates Acute Lung Injury in Mice
- The effects of marijuana exposure on expiratory airflow. A study of adults who participated in the U.S. National Health and Nutrition Examination Study
- Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis
- The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
- Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis
- Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis
- A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis
- Cannabinoids: novel therapies for arthritis?
- Cannabinoids as novel anti-inflammatory drugs
- A clinical comparison of schizophrenia with and without pre-onset cannabis use disorder: a retrospective cohort study using categorical and dimensional approaches
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice
- Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
- Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain
- Cannabinoids for the Treatment of Schizophrenia: An Overview
- Cannabinoids and schizophrenia: therapeutic prospects
- Activation of Cannabinoid Receptor 2 Enhances Osteogenic Differentiation of Bone Marrow Derived Mesenchymal Stem Cells
- Cannabinoid receptors and the regulation of bone mass
- Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro
- Effects of deleting cannabinoid receptor-2 on mechanical and material properties of cortical and trabecular bone
- Peripheral cannabinoid receptor, CB2, regulates bone mass
- Protective Effects of Cannabidiol on Lesion-Induced Intervertebral Disc Degeneration
- Role of cannabinoids in the regulation of bone remodeling
- The Role Of Type 2 Cannabinoid Receptor In Bone Metabolism
- Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes
- The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities
- The growing trend of cannabidiol in skincare products
- Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System
- A Longitudinal Study of Prenatal Marijuana Use
- A Pilot Study into the Effects of the CB1 Cannabinoid Receptor Agonist WIN55,212-2 or the Antagonist-Inverse Agonist AM251 on Sleep in Rats
- Administration of URB597, Oleoylethanolamide or Palmitoylethanolamide Increases Waking and Dopamine in Rats
- Around‐the‐Clock Oral THC Effects on Sleep in Male Chronic Daily Cannabis Smokers
- Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism
- Effect of Δ-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults
- Endocannabinoid Signaling Regulates Sleep Stability
- Intrahippocampal administration of anandamide increases REM sleep
- Modulation of Sleep-Wake Cycles in Mice and Rats with Cannabinoids
- Proof of concept trial of dronabinol in obstructive sleep apnea
- A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
- Cannabinoids in the management of spasticity associated with multiple sclerosis
- Clinical experiences with cannabinoids in spasticity management in multiple sclerosis
- Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study
- Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation
- Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial
- Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity
- Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review
- Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
- Activation of Cannabinoid CB2 Receptor–Mediated AMPK-CREB Pathway Reduces Cerebral Ischemic Injury
- Activation of cortical type 2 cannabinoid receptors ameliorates ischemic brain injury
- Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion
- Acute upregulation of neuronal mitochondrial type-1 cannabinoid receptor and it’s role in metabolic defects and neuronal apoptosis after TBI
- Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury
- Cannabinoid agonist rescues learning and memory after a traumatic brain injury
- Cannabinoid receptors and the regulation of bone mass
- Cannabis Responsive Head Injury Induced Mutiple Disabilities: A Case Report
- CB1 and CB2 Cannabinoid Receptor Antagonists Prevent Minocycline-Induced Neuroprotection Following Traumatic Brain Injury in Mice
- Early increase of cannabinoid receptor density after experimental traumatic brain injury in the newborn piglet
- Effects of Cannabidiol and Hypothermia on Short-Term Brain Damage in New-Born Piglets after Acute Hypoxia-Ischemia
- Endocannabinoids and traumatic brain injury
- Estradiol Decreases Cortical Reactive Astrogliosis after Brain Injury by a Mechanism Involving Cannabinoid Receptors
- HU211, a Novel Noncompetitive NMethylDAspartate Antagonist, Improves Neurological Deficit and Reduces
- Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat
- Injury, Pain, and Prescription Opioid Use Among Former National Football League (NFL) Players
- Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT1A and CB2 receptors
- Peripheral cannabinoid receptor, CB2, regulates bone mass
- Role of cannabinoids in the regulation of bone remodeling
- The Cannabinoid Agonist Win55212 Reduces Brain Damage in an In Vivo Model of Hypoxic-Ischemic Encephalopathy in Newborn Rats
- The endocannabinoid 2-AG protects the blood–brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines
- The Role Of Type 2 Cannabinoid Receptor In Bone Metabolism
- Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke
- Tissue Engineering of Cartilage; Can Cannabinoids Help?
- Update on the Role of Cannabinoid Receptors after Ischemic Stroke
- Clinical Significance of Cannabinoid Receptors CB1 and CB2 Expression in Human Malignant and Benign Thyroid Lesions
- *Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat
- Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid
- *Neuroprotective activity of cannabinoid receptor-2 against oxidative stress and apoptosis in rat pups having experimentally-induced congenital hypothyroidism
- The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
- Type 1 Cannabinoid Receptor-Containing Axons Innervate Hypophysiotropic Thyrotropin-Releasing Hormone-Synthesizing Neurons
- Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid
- An immunohistochemical study of the thyroid parafollicular (C) cells in rats treated with cannabinoids - preliminary investigations
- Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid
- Effect of Marijuana Use on Thyroid Function and Autoimmunity
- The effects of cannabinoids on the endocrine system
- *Cannabinoids for Tourette’s Syndrome (Review)
- Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome
- Cannabinoids reduce symptoms of Tourette’s syndrome
- *Delta 9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: a 6-Week Randomized Trial
- Influence of Treatment of Tourette Syndrome with Δ9-Tetrahydrocannabinol (Δ9-THC) on Neuropsychological Performance
- *Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome
- Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols
- Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients
- Treatment of Tourette syndrome with cannabinoids (Review)
- *Treatment of Tourette-Syndrome with Δ9-Tetrahydrocannabinol (THC): a randomized crossover trial
- Acute upregulation of neuronal mitochondrial type-1 cannabinoid receptor and it’s role in metabolic defects and neuronal apoptosis after TBI
- An endogenous cannabinoid (2-AG) is neuroprotective after brain injury
- Cannabinoid agonist rescues learning and memory after a traumatic brain injury
- CB1 and CB2 Cannabinoid Receptor Antagonists Prevent Minocycline-Induced Neuroprotection Following Traumatic Brain Injury in Mice
- Early increase of cannabinoid receptor density after experimental traumatic brain injury in the newborn piglet
- Endocannabinoids and traumatic brain injury
- Estradiol Decreases Cortical Reactive Astrogliosis after Brain Injury by a Mechanism Involving Cannabinoid Receptors
- Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist
